Core Insights - Penumbra, Inc. (NYSE:PEN) is recognized as one of the top medical device stocks to invest in, with Needham upgrading its rating from Hold to Buy and setting a price target of $326, driven by expected revenue growth in 2026 [1][2] Revenue Growth Factors - The anticipated revenue growth is attributed to four key factors: the launch of the Ruby XL, findings from the STORM-PE trial, the upcoming Thunderbolt product launch, and reduced headwinds in China [1] - The Thunderbolt product is projected to nearly double Penumbra's revenue per stroke procedure, which is expected to enhance growth in neuro thrombectomy and improve gross margins [2] Company Overview - Penumbra, Inc. is a California-based leader in thrombectomy and vascular intervention technologies, offering products such as the Indigo and Lightning series, along with neuro and vascular embolization solutions [3]